REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 6:10 AM PT / 9:10 AM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/. About P ...

Shares of Pulmonx Corporation (LUNG) have gained 1.6% over the past four weeks to close the last trading session at $7.12, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.50 indicates a potential upside of 89.6%.The average comprises six short-term price targets ranging from a low of $10 to a high of $17, with a standard deviation of $3.21. While the lowest estimate indicate ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39562 PULMONX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0424412 (State or other ...

Pulmonx Corporation (NASDAQ:LUNG) Q3 2024 Earnings Call October 30, 2024 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations Steven Williamson - President and Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler Zachary Day - Canaccord Genuity Frank Takkinen - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the Pulmonx Third Quarter 2024 Earnings Conference Call. [Operator Instructi ...

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.28%. A quarter ago, it was expected that this company would post a loss of $0.41 per share when it actually produced a loss of $0.39, delivering a surprise of 4.88%. Over the last four quarters, the company has sur ...

CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year durability data from LIBERATE study demonstrate positive, durable benefits to patients treated with Zephyr® Valves REDWOOD CITY, Calif. & VIENNA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for severe lung disease, announced the presentation of clinical data from the AeriSeal® CONVERT trial and 5- ...

DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA THOUSAND OAKS, Calif., Sept. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE®) molecule, at the 2024 World Confe ...

REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Lake Street 8th Annual Best Ideas Growth Conference in New York on Thursday, September 14, 2024. About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD ...

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company's key products include the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform, which are designed to assess and treat severe emphysema/COPD patients [2] - The Zephyr Valve has received FDA pre-market approval and is commercially available in over 25 countries, widely recognized as a standard of care treatment option for severe emphysema [2] Upcoming Event - Pulmonx will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference in Boston on September 5, 2024, at 1:30 PM PT / 4:30 PM ET [1] - A live and archived webcast of the presentation will be available on the "Investors" section of the Pulmonx website [1]

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share LUNG The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE S ...